On October 23rd, the European Huntington Association held an engaging and informative webinar titled “Research Insights: Latest Updates on Ongoing Studies.” The session was expertly moderated by Professor Åsa Petersén, an HD clinician and researcher, and included participation from key representatives of Prilenia, Uniqure, PTC Therapeutics and Wave Life Sciences, companies leading the charge in HD clinical trials.
The webinar provided a comprehensive overview of the latest developments in clinical trials, with each company sharing updates and preliminary insights from their ongoing or completed studies in HD treatment. These presentations underscored the diversity of approaches and the progress being made across therapeutic areas.
The session concluded with a Q&A, where attendees had the opportunity to pose questions directly to the panel, facilitating a valuable discussion on the current state and future potential of HD research.
This webinar is part of EHA’s ongoing commitment to keeping the HD community informed about cutting-edge research efforts aimed at improving the lives of those affected by Huntington’s disease.
– Article written by Beatriz Campaniço